CEBP Frontiers in Cancer Prevention Research - 2008 Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fisher, J. A.
Right arrow Articles by Troxel, A. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fisher, J. A.
Right arrow Articles by Troxel, A. B.
Cancer Epidemiology Biomarkers & Prevention Vol. 15, 108-113, January 2006
© 2006 American Association for Cancer Research

Cutting Cost and Increasing Access to Colorectal Cancer Screening: Another Approach to Following the Guidelines

Judith A. Fisher1, Christopher Fikry3 and Andrea B. Troxel2

Departments of 1 Family Practice and Community Medicine and 2 Biostatistics and Epidemiology, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania; and 3 The Boston Consulting Group, New York, New York

Requests for reprints: Judith A. Fisher, Department of Family Practice and Community Medicine, University of Pennsylvania, School of Medicine, 6th Floor Mutch Building, 39th and Market Streets, Philadelphia, PA 19104. Phone: 215-265-9601; Fax: 215-243-3290. E-mail: Judith.Fisher{at}uphs.upenn.edu.

Context: Through medical decision making, physicians in the U.S. influence the spending of >$1.3 trillion or 15% of the gross domestic product. U.S. physicians are challenged to identify areas of clinical practice to improve while cutting cost and increasing access. Primary screening for colorectal cancer is a good example to illustrate this point.

Objective: To apply a population-based method of medical decision making in the area of primary screening for colorectal cancer in order to illustrate a reduction in health care costs while increasing access and maintaining quality of care.

Design: We used a combination of (a) census population data, (b) National Cancer Institute Survey data on screening rates, and (c) charge data to estimate the current costs of colorectal cancer screening. We also estimated cost and capacity increases that would occur under various other screening scenarios. These included all currently screened subjects receiving annual fecal occult blood testing (FOBT), all currently unscreened individuals undergoing either colonoscopy every decade or annual FOBT, and all eligible subjects undergoing annual FOBT.

Main outcome measures: Cost and access differences between current screening activity and other potential scenarios compliant with guidelines.

Results: Screening for colorectal cancer with yearly, six-window, rehydrated FOBT for all normal-risk individuals over the age of 50 has the potential to screen 3,813,095 more Americans for colon cancer yearly than are currently being screened, while costing $8.7 billion less per decade than what is currently being spent on screening a fraction of the population. Looking into the future, it is possible to increase screening rates from 50% to 100%, while saving almost $10 billion per decade by using FOBT for all eligible Americans. In practice, some proportion of these benefits would be realized as the calculations assume a 100% patient compliance rate.

Conclusions: Considering a population-based approach and the balance among quality, accessibility, and cost parameters, we recommend primary screening for colorectal cancer to be based on yearly six-window, rehydrated FOBT. Colonoscopy due to cost and access issues should be relegated to secondary screening and case finding. (Cancer Epidemiol Biomarkers Prev 2006;15(1):108–13)




This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. E. Maxwell, L. L. Danao, C. M. Crespi, C. Antonio, G. M. Garcia, and R. Bastani
Disparities in the Receipt of Fecal Occult Blood Test versus Endoscopy among Filipino American Immigrants
Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 1963 - 1967.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
A. F. Jerant, J. J. Fenton, and P. Franks
Determinants of Racial/Ethnic Colorectal Cancer Screening Disparities
Arch Intern Med, June 23, 2008; 168(12): 1317 - 1324.
[Abstract] [Full Text] [PDF]


Home page
Crit Care NurseHome page
M. E. Pelleschi
Clostridium difficile-Associated Disease: Diagnosis, Prevention, Treatment, and Nursing Care
Crit. Care Nurse, February 1, 2008; 28(1): 27 - 35.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.